These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9224642)

  • 1. Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1).
    Nagase H; Suzuki K; Cawston TE; Brew K
    Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):163-7. PubMed ID: 9224642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.
    Huang W; Meng Q; Suzuki K; Nagase H; Brew K
    J Biol Chem; 1997 Aug; 272(35):22086-91. PubMed ID: 9268350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
    Gomis-Rüth FX; Maskos K; Betz M; Bergner A; Huber R; Suzuki K; Yoshida N; Nagase H; Brew K; Bourenkov GP; Bartunik H; Bode W
    Nature; 1997 Sep; 389(6646):77-81. PubMed ID: 9288970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase.
    Itoh Y; Nagase H
    J Biol Chem; 1995 Jul; 270(28):16518-21. PubMed ID: 7622455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A.
    Nguyen Q; Willenbrock F; Cockett MI; O'Shea M; Docherty AJ; Murphy G
    Biochemistry; 1994 Mar; 33(8):2089-95. PubMed ID: 8117665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.
    Raeeszadeh-Sarmazdeh M; Greene KA; Sankaran B; Downey GP; Radisky DC; Radisky ES
    J Biol Chem; 2019 Jun; 294(24):9476-9488. PubMed ID: 31040180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin.
    Baragi VM; Fliszar CJ; Conroy MC; Ye QZ; Shipley JM; Welgus HG
    J Biol Chem; 1994 Apr; 269(17):12692-7. PubMed ID: 8175679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors.
    Nagase H; Brew K
    Biochem Soc Symp; 2003; (70):201-12. PubMed ID: 14587293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.
    Batra J; Robinson J; Soares AS; Fields AP; Radisky DC; Radisky ES
    J Biol Chem; 2012 May; 287(19):15935-46. PubMed ID: 22427646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between the appearance of gelatinases in the synovial fluid of patients with rheumatoid arthritis and polymorphonuclear elastase, stromelysin-1, and the tissue inhibitor of metalloproteinase-1.
    Watanabe Y; Shimamori Y; Fujii N; Yamaguchi R; Fujimoto Y; Matsuno H
    Clin Exp Rheumatol; 1997; 15(3):255-61. PubMed ID: 9177919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
    Wei S; Chen Y; Chung L; Nagase H; Brew K
    J Biol Chem; 2003 Mar; 278(11):9831-4. PubMed ID: 12515831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-function relationships in the tissue inhibitors of metalloproteinases.
    Willenbrock F; Murphy G
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 2):S165-70. PubMed ID: 7952654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.
    Iyer S; Wei S; Brew K; Acharya KR
    J Biol Chem; 2007 Jan; 282(1):364-71. PubMed ID: 17050530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIMP-1 contact sites and perturbations of stromelysin 1 mapped by NMR and a paramagnetic surface probe.
    Arumugam S; Hemme CL; Yoshida N; Suzuki K; Nagase H; Berjanskii M; Wu B; Van Doren SR
    Biochemistry; 1998 Jul; 37(27):9650-7. PubMed ID: 9657677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).
    Vallon R; Müller R; Moosmayer D; Gerlach E; Angel P
    Eur J Biochem; 1997 Feb; 244(1):81-8. PubMed ID: 9063449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin.
    Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R
    Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
    Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
    J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T; Okada Y; Nakanuma Y
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
    Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
    J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3.
    Wu Y; Wei S; Van Doren SR; Brew K
    J Biol Chem; 2011 May; 286(19):16891-9. PubMed ID: 21454617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.